Feedback within the inter-cellular communication and tumorigenesis in carcinomas

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Rückert, Felix ^a   Grützmann, Robert ^a   Pilarsky, Christian ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOGENESIS; CARCINOMA; CARCINOMA CELL; CELL COMMUNICATION; CELL DAMAGE; CELL STIMULATION; CELLULAR STRESS RESPONSE; CLASSICAL SOMATIC MUTATION THEORY; DISEASE COURSE; EPITHELIUM CELL; HUMAN; INFLAMMATORY CELL; NONHUMAN; PANCREAS ADENOCARCINOMA; PARENCHYMA; PATHOPHYSIOLOGY; POSITIVE FEEDBACK; SIGNAL TRANSDUCTION; STROMA CELL; THEORY; TUMOR MICROENVIRONMENT;

EID: 84872097700     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036719     Document Type: Article

References (71)

1. Bergers G, Hanahan D, Coussens LM, (1998) Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int J Dev Biol 42: 995-1002.
2. Vogelstein B, Kinzler KW, (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799.
3. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
4. Renan MJ, (1993) How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 7: 139-146.
5. Cho KR, Vogelstein B, (1992) Genetic alterations in the adenoma-carcinoma sequence. Cancer 70: 1727-1731.
6. Bissell MJ, Radisky D, (2001) Putting tumours in context. Nat Rev Cancer 1: 46-54.
7. Sonnenschein C, Soto AM, (2011) The death of the cancer cell. Cancer Res 71: 4334-4337.
8. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, et al. (2007) Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 7: 246-255.
9. Kenny PA, Lee GY, Bissell MJ, (2007) Targeting the tumor microenvironment. Front Biosci 12: 3468-3474.
10. Pupa SM, Menard S, Forti S, Tagliabue E, (2002) New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 192: 259-267.
11. Bissell MJ, Hines WC, (2011) Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17: 320-329.
12. Radisky D, Hagios C, Bissell MJ, (2001) Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol 11: 87-95.
13. Axelrod R, Axelrod DE, Pienta KJ, (2006) Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A 103: 13474-13479.
14. Liotta LA, Kohn EC, (2001) The microenvironment of the tumour-host interface. Nature 411: 375-379.
15. Fausto N, (2000) Liver regeneration. J Hepatol 32: 19-31.
16. Bardeesy N, DePinho RA, (2002) Pancreatic cancer biology and genetics. Nat Rev Cancer 2: 897-909.
17. Shibata D, Almoguera C, Forrester K, Dunitz J, Martin SE, et al. (1990) Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res 50: 1279-1283.
18. Dergham ST, Dugan MC, Kucway R, Du W, Kamarauskiene DS, et al. (1997) Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol 21: 127-143.
19. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, et al. (2003) Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22: 3243-3251.
20. McGrath JP, Capon DJ, Smith DH, Chen EY, Seeburg PH, et al. (1983) Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene. Nature 304: 501-506.
21. Arvanitakis M, Van Laethem JL, Parma J, De Maertelaer V, Delhaye M, et al. (2004) Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation. Endoscopy 36: 535-542.
22. Ghosh S, Hayden MS, (2008) New regulators of NF-kappaB in inflammation. Nat Rev Immunol 8: 837-848.
23. Karin M, (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
24. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, et al. (2011) Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 167: e211-219.
25. Greer JB, Whitcomb DC, (2009) Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharmacol 9: 411-418.
26. Wullaert A, Bonnet MC, Pasparakis M, (2011) NF-kappaB in the regulation of epithelial homeostasis and inflammation. Cell Res 21: 146-158.
27. Goecke H, Forssmann U, Uguccioni M, Friess H, Conejo-Garcia JR, et al. (2000) Macrophages infiltrating the tissue in chronic pancreatitis express the chemokine receptor CCR5. Surgery 128: 806-814.
28. Hymowitz SG, Wertz IE, (2010) A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer 10: 332-341.
29. Sethi G, Aggarwal BB, (2006) Role of NF-kB and NF-kB-regulated Gene Products in Chemoresistance and Radioresistance. Curr Cancer Ther Rev 2.
30. Gyorffy B, Schafer R, (2010) Biomarkers downstream of RAS: a search for robust transcriptional targets. Curr Cancer Drug Targets 10: 858-868.
31. Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, et al. (2003) Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene 22: 2478-2492.
32. Morris JPt, Wang SC, Hebrok M, (2010) KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 10: 683-695.
33. Friday BB, Adjei AA, (2005) K-ras as a target for cancer therapy. Biochim Biophys Acta 1756: 127-144.
34. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, et al. (2012) Kras(G12D)-Induced IKK2/beta/NF-kappaB Activation by IL-1alpha and p62 Feedforward Loops Is Required for Development of Pancreatic Ductal Adenocarcinoma. Cancer Cell 21: 105-120.
35. Weinberg RA, (1998) One renegade cell: How cancer begins. New York NY: Basic Books.
36. Stratton MR, (2011) Exploring the genomes of cancer cells: progress and promise. Science 331: 1553-1558.
37. Ruckert F, Aust D, Bohme I, Werner K, Brandt A, et al. (2011) Five Primary Human Pancreatic Adenocarcinoma Cell Lines Established by the Outgrowth Method. J Surg Res.
38. Rückert F, Pilarsky C, Grützmann R, (2011) Establishment of primary cell lines in pancreatic cancer; Srivastava SK, editor. Rijeka InTech.
39. Dvorak HF, (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1659.
40. Jackson L, Evers BM, (2006) Chronic inflammation and pathogenesis of GI and pancreatic cancers. Cancer Treat Res 130: 39-65.
41. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A, (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073-1081.
42. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, et al. (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11: 291-302.
43. Fendrich V, Chen NM, Neef M, Waldmann J, Buchholz M, et al. (2010) The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 59: 630-637.
44. Talar-Wojnarowska R, Malecka-Panas E, (2006) Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit 12: RA186-193.
45. Magee CJ, Greenhalf W, Howes N, Ghaneh P, Neoptolemos JP, (2001) Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications. Surg Oncol 10: 1-23.
46. Lowenfels AB, Maisonneuve P, (2006) Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 20: 197-209.
47. Park CC, Bissell MJ, Barcellos-Hoff MH, (2000) The influence of the microenvironment on the malignant phenotype. Mol Med Today 6: 324-329.
48. Farrow B, Albo D, Berger DH, (2008) The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res 149: 319-328.
49. Bachem MG, Schunemann M, Ramadani M, Siech M, Beger H, et al. (2005) Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128: 907-921.
50. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436-444.
51. Balkwill F, (2004) Cancer and the chemokine network. Nat Rev Cancer 4: 540-550.
52. Langley RR, Fidler IJ, (2007) Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 28: 297-321.
53. Naumov GN, MacDonald IC, Weinmeister PM, Kerkvliet N, Nadkarni KV, et al. (2002) Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 62: 2162-2168.
54. Nowell PC, (2002) Tumor progression: a brief historical perspective. Semin Cancer Biol 12: 261-266.
55. Guarino M, Tosoni A, Nebuloni M, (2009) Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition. Hum Pathol 40: 1365-1376.
56. Kalluri R, Weinberg RA, (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
57. Savagner P, Arnoux V, (2009) [Epithelio-mesenchymal transition and cutaneous wound healing]. Bull Acad Natl Med 193 1981-1991; discussion 1992.
58. Coussens LM, Fingleton B, Matrisian LM, (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.
59. Eccles SA, Welch DR, (2007) Metastasis: recent discoveries and novel treatment strategies. Lancet 369: 1742-1757.
60. Parsons DF, Marko M, Wansor KJ, (1983) Inflammation with restricted lysosomal proteolysis during early ascites carcinoma invasion of mouse parietal peritoneum. A medium and high-voltage electron microscopic and cytochemical study. Tissue Cell 15: 499-507.
61. Paget S, (1889) The distribution of secondary growths in cancer of the breast. Lancet 1: 571-573.
62. Ewing J, (1928) Neoplastic diseases. 6th Edition. Philadelphia WB Saunders.
63. Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, et al. (1984) Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 44: 3584-3592.
64. Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, et al. (2003) The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 63: 7451-7461.
65. Lee YT, Tatter D, (1984) Carcinoma of the pancreas and periampullary structures. Pattern of metastasis at autopsy. Arch Pathol Lab Med 108: 584-587.
66. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
67. Lee CJ, Dosch J, Simeone DM, (2008) Pancreatic cancer stem cells. J Clin Oncol 26: 2806-2812.
68. Ruckert F, Aust D, Bohme I, Werner K, Brandt A, et al. (2012) Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. J Surg Res 172: 29-39.
69. Bilimoria MM, Lauwers GY, Doherty DA, Nagorney DM, Belghiti J, et al. (2001) Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 136: 528-535.
70. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457-1461.
71. Sporn MB, (2011) Perspective: The big C- for Chemoprevention. Nature 471: S10-11.